Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells

Fig. 3

Induction of T cell activation by MIL-38-CD3 BiTE. T cell activation was measured by flow cytometry analysis of CD69 (a) or CD25 (c) in T cells (within PBMCs) cultured with MIL-38-CD3 BiTE and GPC-1high DU-145 cells within the CD3+CD4+ or CD3+CD8+ T cell gates (a) or GPC-1low C3 cells (b: CD69; d: CD25) at a ratio of 10:1 PBMC:tumour cell for 24 h. Data are representative of more than 2 independent experiments. ****p < 0.0001; ***p < 0.001; **p < 0.01

Back to article page